Association between infliximab trough levels and the occurrence of paradoxical manifestations in patients with inflammatory bowel disease: A case-control study

Journal of Crohn's and Colitis

Volumn 9, Issue 11, 2015, Pages 982-987

  Coutzac, C ^a   Chapuis, J ^a   Poullenot, F ^a   Chabrun, E ^a   Capdepont, M ^a   Blanco, P ^b   Laharie, David ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

Crohn's disease; inflammatory bowel disease; Infliximab; infliximab trough level; paradoxical manifestations; psoriasis; ulcerative colitis

Indexed keywords

ANTINUCLEAR ANTIBODY; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; GASTROINTESTINAL AGENT;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; CASE CONTROL STUDY; CLINICAL FEATURE; CONTROLLED STUDY; CROHN DISEASE; CROSS-SECTIONAL STUDY; CUTANEOUS PARADOXICAL MANIFESTATION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; ECZEMA; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; RHEUMATIC DISEASE; RHEUMATOLOGICAL PARADOXICAL MANIFESTATION; SMOKING; STATISTICS; VERY ELDERLY; ADVERSE EFFECTS; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; COMPLICATION; INFLAMMATORY BOWEL DISEASES; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; LOGISTIC MODELS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; YOUNG ADULT;

EID: 84963779284     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv159     Document Type: Article

References (38)

1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9
3. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
4. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel J-F. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-53
5. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85
6. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008;1:CD006893
7. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58:501-8
8. Caspersen S, Elkjaer M, Riis L, et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008;6:1212-7
9. Colombel J-F, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31
10. Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel J-F. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008;57:549-58
11. Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha [TNF-a] inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013;108:99-105
12. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012;143:390-9
13. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatol Treat 2009;20:100-8
14. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003;125:32-9
15. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebocontrolled trial. J Am Acad Dermatol 2004;51:534-42
16. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, doubleblind trial. Lancet 2005;366:1367-74
17. Viguier M, Richette P, Bachelez H, Wendling D, Aubin F. [Paradoxical cutaneous manifestations during anti-TNF-alpha therapy]. Ann Dermatol Vénéréologie 2010;137:64-71
18. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59:996-1001
19. Rahier J-F, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010;8:1048-55
20. Fréling E, Baumann C, Cuny JF, Bigard MA, Schmutz JL, Barbaud A, Peyrin-Biroulet L. Cumulative Incidence of, Risk Factors for, and Outcome of Dermatological Complications of Anti-TNF Therapy in Inflammatory Bowel Disease: A 14-Year Experience. Am J Gastroenterol. 2015 Aug;110(8):1186-96
21. Van Moerkercke W, Ackaert C, Kasran A, Ballet V. Severe auto-immune driven arthralgia as a new side effect in anti-TNFα treated IBD patients? In: abstracts from the 5th ECCO Congress; February 2011; Dublin
22. Subramanian S, Yajnik V, Sands BE, Cullen G, Korzenik JR. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis 2011;17:99-104
23. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010;4:355-66
24. Chowers Y, Sturm A, Sans M, et al. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis 2010;4:367-76
25. Van Assche G, Dignass A, Panes J, et al. The second European evidencebased Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis 2010;4:7-27
26. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010;4:28-62
27. Satsangi J, Silverberg MS, Vermeire S, Colombel J-F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-53
28. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514
29. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-86
30. Cleynen I, Van Moerkercke W, Juergens M. Anti-TNF induced cutaneous lesions in IBD patients: characterization and search for predisposing factors. Gut 2010;59:A1
31. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol 2012;9:496-503
32. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005;202:135-43
33. Seneschal J, Milpied B, Vergier B, Lepreux S, Schaeverbeke T, Taïeb A. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol;161:1081-8
34. Ma H-L, Napierata L, Stedman N, et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum 2010;62:430-40
35. Nancey S, Blanvillain E, Parmentier B, et al. Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease. Inflamm Bowel Dis 2005;11:986-91
36. Beigel F, Schnitzler F, Paul Laubender R, et al. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-a antibody-treated patients with inflammatory bowel disease. Inflamm Bowel Dis 2011;17:91-8
37. Afif W, Loftus EV, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:1133-9
38. Huang V, Dhami N, Fedorak D, et al. A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels. Can J Gastroenterol Hepatol 2015;29:35-40